Beyond Cancer, eine Tochtergesellschaft von Beyond Air Inc., wird auf der AACR-Jahrestagung 2026 Phase-1-Daten zur intratumoralen Verabreichung von ultra-hochkonzentriertem Stickstoffmonoxid (UNO) bei soliden Tumormetastasen präsentieren.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9648507) on February 04, 2026, and is solely responsible for the information contained therein.
Comments